Search

Ultragenyx Pharmaceutical Inc

Lezárt

SzektorEgészségügy

35.83 5.91

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

32.76

Maximum

34.17

Fő mutatók

By Trading Economics

Bevétel

-56M

-185M

Értékesítés

-71M

136M

Egy részvényre jutó nyereség

-1.54

Profit margin

-136.029

Munkavállalók

1,371

EBITDA

-50M

-155M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+60.65% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

582M

3B

Előző nyitás

29.92

Előző zárás

35.83

Hangulat hírek alapján

By Acuity

57%

43%

293 / 342 Rangsor szerint Healthcare

Ultragenyx Pharmaceutical Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. júl. 6. 23:41 UTC

Correlated Moves
Social Media
News

Micron Technology shares are lower in after-market trading, reflecting broader market pressures and concerns over a potential memory oversupply by 2028.

2026. júl. 6. 23:31 UTC

Correlated Moves
News
Social Media

Microsoft Corp announced layoffs of about 4,800 employees, primarily in its Xbox division. Shares are lower in after-market trading following the news.

2026. júl. 6. 23:26 UTC

Correlated Moves
News

Analog Devices Inc. is advancing in after-market trading, driven by a rebound in the semiconductor sector and bullish updates from UBS and Goldman Sachs.

2026. júl. 6. 23:02 UTC

Social Media
News

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

2026. júl. 6. 20:51 UTC

News
Correlated Moves

Invesco CurrencyShares Euro Trust is gaining in after-market trading, influenced by comments from Federal Reserve Governor Christopher Waller on monetary policy complexities.

2026. júl. 6. 20:07 UTC

News

Verisign shares are higher amid reported $1.1 billion in free cash flow, though concerns linger over AI advancements and upcoming contract renewals.

2026. júl. 6. 20:07 UTC

News
Social Media

Netflix Inc faces engagement issues, prompting bearish investor sentiment. The stock is trading lower amid concerns ahead of its upcoming earnings report.

2026. júl. 6. 20:07 UTC

Social Media
News
Macro Event

PayPal Holdings Inc. shares are lower as recent ISM Services data showed a slowdown in growth, with the PMI declining from the previous month.

2026. júl. 6. 20:07 UTC

Correlated Moves
News

Ethereum is advancing, supported by Tom Lee's BitMine purchasing $74 million in the asset, raising their total holdings to 5,742,237 ETH.

2026. júl. 6. 20:07 UTC

Correlated Moves
News

Bitcoin trades higher, recovering from earlier lows, amid stable cryptocurrency market conditions and concerns over inflation and interest rates. Current price is $61,750.

2026. júl. 6. 20:07 UTC

News
Correlated Moves

Bitcoin's value has risen since Sunday, reaching around $61,750. This increase occurs amid broader cryptocurrency market weakness and concerns over inflation and interest rates.

2026. júl. 6. 20:07 UTC

Social Media
News

Adobe Inc. shares are lower amid scrutiny of first-quarter results and competitive pressures from Canva and Figma, with support noted at $215.

2026. júl. 6. 20:07 UTC

News
Social Media

Apple Inc. shares are higher following an extended partnership with Broadcom for custom chips through 2031 and the reintroduction of card payments in India.

2026. júl. 6. 20:06 UTC

Event
News

Cisco Systems Inc shares are higher today as the company went ex-dividend, distributing $0.42 per share, amid positive analyst upgrades.

2026. júl. 6. 20:06 UTC

News

Ulta Beauty Inc. shares are lower amid declines in the Other Specialty Retail sub-sector and broader market weakness, trading near the bottom of its one-month range.

2026. júl. 6. 20:06 UTC

Social Media
News

Scotiabank upgraded Check Point Software to Sector Outperform, setting a price target of $185, following its 2025 ESG Report release. Shares are higher since Thursday's close.

2026. júl. 6. 20:06 UTC

News

Cintas Corp shares are lower today, continuing a broader market decline since Thursday. The stock peaked early but has trended downward since.

2026. júl. 6. 20:06 UTC

News

Cadence Design Systems reported first-quarter revenue of $1.474 billion, an 18.7% year-over-year increase, and a record backlog of $8 billion. Shares are trading higher.

2026. júl. 6. 20:06 UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

2026. júl. 6. 20:04 UTC

News
Social Media

Tesla shares are higher today, fueled by strong second-quarter delivery figures and the positive reception of its robotaxi service in Miami.

2026. júl. 6. 20:02 UTC

News

Align Technology shares are higher today following a rating upgrade to "strong-buy" from Wall Street Zen, despite a downgrade from Weiss Ratings.

2026. júl. 6. 20:02 UTC

News

Mondelez International shares are lower amid weakness in the Packaged Foods & Meats sector. The stock remains near the lower end of its one-month trading range.

2026. júl. 6. 20:02 UTC

News
Social Media
Correlated Moves

Qualcomm's stock rises as Nvidia's CEO endorses its AI tech and Bernstein raises its price target. A partnership with Meta also boosts investor interest.

2026. júl. 6. 20:02 UTC

News
Social Media

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

2026. júl. 6. 20:02 UTC

Macro Event
News

J B Hunt shares decline after Morgan Stanley downgraded the stock to Underweight, raising the price target to $200 from $190 amid sector concerns.

2026. júl. 6. 19:57 UTC

News
Social Media

Berkshire Hathaway has tripled its stake in Alphabet, boosting investor sentiment. Alphabet's inclusion in the Dow Jones further underscores its growth potential.

2026. júl. 6. 19:56 UTC

News

Natural gas is trading higher today, maintaining an upward trajectory above its 20-day moving average. ProShares Ultra Bloomberg Natural Gas has gained since Thursday's close.

2026. júl. 6. 19:53 UTC

News

Charter Communications Inc is declining amid low demand for services and stagnant returns on capital. Analysts rate the stock as "Reduce," reflecting a cautious outlook.

2026. júl. 6. 19:52 UTC

Social Media
News

Evercore ISI raised its price target on Illumina to $200, maintaining an Outperform rating. Shares are trading higher amid positive sentiment and social media discussions.

2026. júl. 6. 19:51 UTC

Social Media
News

Bank of America upgraded T-Mobile US Inc to Buy, maintaining a $220 price target, citing overstated competition concerns and the company's urban market dominance.

Társak összehasonlítása

Árváltozás

Ultragenyx Pharmaceutical Inc Előrejelzés

Célár

By TipRanks

60.65% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 54.14 USD  60.65%

Magas 96 USD

Alacsony 26 USD

15 Wall Street elemző 12 hónapos célárain alapulva a(z)Ultragenyx Pharmaceutical Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

15 ratings

14

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

293 / 342 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
help-icon Live chat